Accelerating Biologics Manufacturing by Modeling or: Is Approval under the QbD and PAT Approaches Demanded by Authorities Acceptable without a Digital-Twin?
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Innovative biologics, including cell therapeutics, virus-like particles, exosomes, recombinant proteins, and peptides, seem likely to substitute monoclonal antibodies as the main therapeutic entities in manufacturing over the next decades. This molecular variety causes a growing need for a general change of methods as well as mindset in the process development stage, as there are no platform processes available such as those for monoclonal antibodies. Moreover, market competitiveness demands hyper-intensified processes, including accelerated decisions toward batch or continuous operation of dedicated modular plant concepts. This indicates gaps in process comprehension, when operation windows need to be run at the edges of optimization. In this editorial, the authors review and assess potential methods and begin discussing possible solutions throughout the workflow, from process development through piloting to manufacturing operation from their point of view and experience. Especially, the state-of-the-art for modeling in red biotechnology is assessed, clarifying differences and applications of statistical, rigorous physical-chemical based models as well as cost modeling. “Digital-twins” are described and efforts vs. benefits for new applications exemplified, including the regulation-demanded QbD (quality by design) and PAT (process analytical technology) approaches towards digitalization or industry 4.0 based on advanced process control strategies. Finally, an analysis of the obstacles and possible solutions for any successful and efficient industrialization of innovative methods from process development, through piloting to manufacturing, results in some recommendations. A central question therefore requires attention: Considering that QbD and PAT have been required by authorities since 2004, can any biologic manufacturing process be approved by the regulatory agencies without being modeled by a “digital-twin” as part of the filing documentation?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
About The Importance of Autonomy and Digital Twins for the Future of Manufacturing
Rosen, R., von Wichert, G., Lo, G., & Bettenhausen, K. D. (2015) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2015.06.141 · Cited by 1,474
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Efficient production and enhanced tumor delivery of engineered extracellular vesicles
Watson, D. C., Bayik, D., Srivatsan, A., Bergamaschi, C., Valentin, A., Niu, G., Bear, J., Monninger, M., Sun, M., Morales-Kastresana, A., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.003 · Cited by 385
McCullagh, P. (2002) · The Annals of Statistics · doi:10.1214/aos/1035844977 · Cited by 248 · cited 1×
“Statistical models: Are part of the evaluation of experimental data generated according to DoE experimental plans, which could be statistically evaluated according to accuracy and prediction by aid of statistical models [51,68].”
MethodMeyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Kornecki, M., & Strube, J. (2018) · Bioengineering · doi:10.3390/bioengineering5010025 · Cited by 61
Self-citationSixt, M., Schmidt, A., Mestmäcker, F., Huter, M. J., Uhlenbrock, L., & Strube, J. (2018) · Processes · doi:10.3390/pr6090161 · Cited by 25
Self-citation
Cited by
Digital twins-based smart manufacturing system design in Industry 4.0: A review
Leng, J., Wang, D., Shen, W., Li, X., Liu, Q., & Chen, X. (2021) · Journal of Manufacturing Systems · doi:10.1016/j.jmsy.2021.05.011 · Cited by 766
Lim, K. Y. H., Zheng, P., & Chen, C.-H. (2020) · Journal of Intelligent Manufacturing · doi:10.1007/s10845-019-01512-w · Cited by 700
Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review
Chen, Y., Yang, O., Sampat, C., Bhalode, P., Ramachandran, R., & Ierapetritou, M. (2020) · Processes · doi:10.3390/pr8091088 · Cited by 278
Noll, P., & Henkel, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.10.018 · Cited by 60
“oppose efforts to benefits of digital twins for applications in biologics manufacturing with regard to the QbD and PAT framework [170].”
BackgroundHelgers, H., Schmidt, A., Lohmann, L. J., Vetter, F. L., Juckers, A., Jensch, C., Mouellef, M., Zobel-Roos, S., & Strube, J. (2021) · Processes · doi:10.3390/pr9010172 · Cited by 52
Self-citation
Metadata
- Authors
- Zobel-Roos, S., Schmidt, A., Mestmäcker, F., Mouellef, M., Huter, M., Uhlenbrock, L., Kornecki, M., Lohmann, L., Ditz, R., & Strube, J.
- Venue
- Processes
- Publisher
- MDPI AG
- Published
- 2019-02-13
- Volume
- 7
- Issue
- 2
- Pages
- 94
- ISSN
- 2227-9717 (ISSN-L)
- OpenAlex
- W2912105837
- Cited by
- 103
- References
- 8
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.